The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback